HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Women's Health Orgs Back Feinstein Bill; Federal Microbeads Ban Gains Support

This article was originally published in The Rose Sheet

Executive Summary

The Personal Care Products Safety Act has the support of 13 national health organizations, which sent a June 25 letter to the bill's sponsor and the Senate Health Committee welcoming federal oversight reform in the sector. More news in brief.

You may also be interested in...



P&G Beauty Businesses Could Be Going Coty's Way, Insiders Say

Coty could soon be the new owner of P&G's Wella and Clairol hair-care businesses, CoverGirl and Max Factor makeup lines and prestige fragrance licenses, significantly growing Coty's global beauty presence, under a deal rumored to be in the works. Coty's stock jumped nearly 15% following reports that it has won an auction to purchase the brands as part of P&G's streamlining initiative.

In Brief: Federal Microbeads Bill Advances; Avon Buyout Hoax? More

The Microbead-Free Waters Act of 2015 was approved via voice vote by the House Energy and Commerce Health Subcommittee May14; Avon says it has not received a buyout offer from PTG Capital Partners despite a May 13 SEC filing from the firm indicating as much. More news in brief.

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019549

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel